GSK's Votrient EU upgrade to drive sales
This article was originally published in Scrip
Executive Summary
European authorities have upgraded the authorization for GlaxoSmithKline's Votrient (pazopanib) from conditional to full, says the firm. It looks as though the news will drive sales and uptake.